Details of the Drug

General Information of Drug (ID: DMNZOJ3)

Drug Name

ALXN1820

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05565092) A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Participants With Sickle Cell Disease. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Alexion